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Summary.-Peripheral blood mononuclear cells will lyse antibody-treated human
erythrocytes. Using Group A red cells and a hyperimmune anti-Al serum, we have
devised a microassay for the cytolytic capacity of mononuclear cell suspensions. The
effector cells responsible for red-cell lysis are mononuclear, adherent and phagocytic,
and their activity is blocked by aggregated IgG. Their presence correlates well with
non-specific esterase-containing cells and we conclude that they are monocytes.
Dose-response curves of red-cell lysis plotted against numbers of monocytes were
used to derive a simple parameter expressing the number of monocytes needed to
lyse 15o% of the 51Cr-labelled red cells.
The assay was applied to a group of 27 normal controls and 36 patients with a
histologically proven diagnosis of malignant melanoma. The results indicate that
monocytes from patients show significantly greater lytic activity than those from the
controls. These data suggest that monocytes from cancer patients are in some way
activated, and that other defects in monocyte function which have been detected in
cancer patients (defective chemotaxis and maturation) may be associated with
monocyte "activation".
THERE is increasing evidence for dis-
ordered monocyte and macrophage func-
tion in cancer patients. Dizon and Southam
(1963), using a skin-window technique,
concluded that patients with malignant
tumours have defective macrophage mobil-
ization. Several studies have subsequently
shown that the monocytes of cancer
patients have defective chemotaxis
(Boetcher and Leonard, 1974; Hausman
et al., 1975; McVie, Logan and Kay, 1977).
Our own studies indicate that the matura-
tion ofmonocytes into macrophages is also
inhibited in cancer patients (Currie and
Hedley, 1977). Counter to this general
theme of depressed monocyte-macrophage
function, Lobuglio (1970) and recently
Rhodes (1977) have shown that the mono-
cytes of cancer patients have increased
expression of surface Fc receptors.
Since Holm and Hammarstrom (1973)
have shown that human peripheral blood
monocytes will lyse antibody-coated
human erythrocytes, we have adapted
this phenomenon to develop an assay for
the detection of disordered monocyte
function in patients with malignant mela-
noma.
MATERIALS AND METHODS
Patients studied.-Blood samples were ob-
tained from 36 patients with a histologically
proven diagnosis of malignant melanoma.
Following detailed clinical investigation, the
untreated patients could be classified into
2 broad groups: 10 patients had clinically
detectable residual, recurrent or disseminated
disease, and 11 patients who, while clinically
"disease-free", had a very high risk of re-
currence, and could therefore be considered
to have minimal residual disease. The blood
samples for assay were taken at least 2 weeks
after any surgery and before cytotoxic
chemotherapy, irradiation or immunologicalR. E. NYHOLM AND G. A. CURRIE
treatment. There w,ere also 19 patients studied
after eytotoxic chemotherapyand/orimmuno-
therapy. Four of these patients were studied
both before andafter cytotoxic chemotherapy.
Samples were also obtained from 27 normal
healthy volunteers.
Preparation of mononuclear cell suspen-
sions. Preliminary experiments indicated
that preservative-free heparin inhibited
monocyte-mediated lysis, and in consequence
all these experiments used defibrinated blood.
About 10 ml of defibrinated venous blood
were diluted and layered on to Ficoll-
Hypaque (Lymphoprep. Nyegaard) and cen-
trifuged as described by Boyum (1968). The
mononuclear cell (MNC) band was carefully
removed, washed x 3 in Medium 199 and
counted in a haemocytometer.
Enzyme cytochemistry.-Samples of the
MNC suspension were placed on to glass
slides, air-dried and fixed in formol-acetone
at 4°C for 30 sec. They were then stained for
non-specific esterase (NSE) and chloro-
acetate esterase (CAE) by the methods of
Yam, Li and Crosby (1971). The slides were
then examined by light microscopy and the
percentage of cells stained was counted.
NSE staining applied to peripheral blood
cell suspensions is a valuable marker of cells
of monocyte lineage, whereas CAE has been
shown by the above authors to be a relatively
specific marker for cells of the granulocyte
series.
Target cells.-Fresh human Group A red
cells were obtained from the same donor in
all the studies and washed X3 in Medium 199.
1-5 x< 107 red cells were incubated in 0-25 ml
of 199 containing 100 ,uCi sodium [51Cr]
chromate (Radiochemical Centre, Amersham)
at 37°C. After 30 min, an equal volume of a
solution of 10% trypsin (Armour Pharma-
ceutical) in 199 was added and the mixture
incubated for a further 30 min. The cells
were then washed X 3 and made up at
2 x 106/ml in 199.
Cytolysis microassay.-The labelled red
cells were added in 50 y1 volumes containing
105 cells to the wells of 3040 microplates
(Falcon Plastics). Serial dilutions of the
MNC suspensions to be tested, ranging from
1-0 to 4 0 x 105 in 50 ,ul, were then added to
the target cells, and were followed by 50 ,u
of diluted anti-A1 serum. This hyperimmune
anti-A1 serum (a generous gift from Mr P. G.
Gill, The Radcliffe Infirmary, Oxford) had
an agglutination titre of >1:2040, and in
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preliminary experiments the optimal con-
centration for monocyte-mediated haemoly-
sis was approximately 1:300, since, as can be
seen in Fig. 1, there was no significant in-
crease in red-cell lysis at concentrations
above 1:500. The antiserum was therefore
diluted 1:100 before addition to the assay.
The antiserum used had no detectable effect
on the lytic capacity of monocytes from
Group A donors. Control wells containing
Medium 199 in place of either antiserum or
effector cells were included in each assay. All
experiments were performed in triplicate
wells.
The microplates were then centrifuged at
80 g for 3 min and incubated at 37°C in
humid air containing 5% CO2 for 2 h. The
plate was then centrifuged again (220 g for
5 min) and 50 ,ul samples of supernatant were
withdrawn from each well and counted in an
automatic gamma counter. The results were
then expressed as a percentage 51Cr release
determined as follows:
% 5ICr release
Release in test well-
Spontaneousreleasex 0
Total releasable- X 100
Spontaneous release
The total releasable 51Cr was measured after
the addition of 5% sodium dodecyl sulphate
(SDS).
RESULTS
The assay as described provided clear
evidence of cell-mediated lysis of the
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target cells in the presence of the anti-
serum. The method was investigated in
some detail before its application to a
series of patients.
.Nature of the effector cell
Ficoll-Hypaque separations yielded
0 5-2 x 106 mononuclear cells (MNC)
from each ml of blood. The percentage of
non-specific esterase (NSE) positive cells
ranged from 7 to 350o. Samples of MNC
suspensions from normal donors were
incubated at 37°C in 25 ml plastic culture
flasks to remove adherent cells. Samples of
the non-adherent cell suspension were
then removed at intervals, and tested
for their capacity to lyse red cells in the
assay system as described. The content of
NSE+ cells was also measured in each
sample. Incubation for 1 h removed all the
NSE+ cells aiid abolished the lytic
capacity of the cell suspension. A typical
experiment shows the effects of progress-
ive removal of adherent cells. 2 x 105
MNC from a normal individual were
added to each well before and after
sequential removal of adherent cells:
Timne of
ir eocbation
(rnin)
0
(3
NSE+ (0°)
34
51Cr
release
(0)
18
4
The effector cell in this assay is therefore
aIn adherent cell.
MNC suspensions were also treated by
agitation with finely diluted carbonyl-iron
powder at 37°C for 20 min, followed by
exposure to a powerful permanent magnet.
This treatment also drastically reduced
both NSE+ cells and the lytic activity of
the cell suspension. This finding indicates
that the effector cells are phagocytic as
well as adherent.
Throughout these studies the controls
(i.e. effector cells without antiserum or
antiserum without effector cells) did
not induice lysis above the backgrotund
spontaneous release, which was always
less than 10% of the total label.
Role ofpolymorphonuclear leucocytes
MNC suspensions, especially those from
thepatients, werefrequently contaminated
with cells of the granulocyte series,
readily identifiable by chloracetate ester-
ase (CAE) staining. To determine the
possible role of these contaminants in the
lysis ofred cells, the following experiments
were performed. Polymorphonuclear leu-
cocyte (PMNL) suspensions were prepared
by subjecting the cell pellet, after removal
of MNCs from Ficoll-Hypaque prepara-
tions, to sedimentation with Dextran 110
at 37°C for 1 h. The unsedimented cells,
>9500 of which were CAE+, were then
tested for haemolytic activity in the
standard assay. As can be seen in Fig. 2,
PMNL were capable of lysing the target
cells, but were considerably less active
than NSE+ cells, up to 4 times more
PMNL than monocytes being needed to
produce 1500 lysis. MNC suspensions
containing up to 10% PMNL, as assessed
by CAE staining, were therefore considered
suitable foi use in the assay, since their
contribution to lysis in the presence of
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FIG. 2. Antibody-dependent lysis ofred cells
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monocytes would be negligible. This
differential capacity to lyse (-..4:1) was
maintained in repeat experiments using
effector cells from normal individuals and
from melanoma patients. However, MNC
preparations containing >10% PMNL
contamination were discarded.
Since PMNL made such a small contri-
bution to the lysis, and since non-adherent
lymphocytes were inactive, we conclude
that the monocyte is the main effector
cell in this assay, a conclusion supported
by the work of Holm and Hammarstrom
(1973).
Mechanism of lysis
Sodium iodoacetamide, a potent inhibi-
tor of glycolysis and phagocytosis (Cohn,
1970), was added to the assay at concentra-
tions not overtly toxic (by trypan blue
test) to the effector cells. This compound
suppressed the lytic activity ofmonocytes,
as can be seen from this representative
experiment in which MNC from a normal
individual were added at 2 x 105 per well:
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FIG. 3.- Effect ofceritrifugation on moniocyte-
medliate(l lysis of redl cells. 0---O,
microplate centrifuged at 80 g for 3 min
before incubation; 0 --, no centrifuga-
tion.
chromatography of ammonium sulphate
serum fractions on Sephadex G-200, were
added in serial dilution to the cytolysis
assay wells, and their effects on red-cell
lysis are shown in Fig. 4. As this diagram
shows, increasing concentrations of the
aggregated but not the monomeric IgG
led to increasing inhibition of lysis. This
The requirement for intimate cell contact
between effector and target cells was
tested by examining the extent of target-
cell lysis in microplates not subjected to
centrifugation before incubation. As can
be seen in Fig. 3, the prior gentle centrifu-
gation is essential to provide significant
lysis after 2 h incubation, suggesting that
close apposition between monocyte and
red cell is necessary for lysis. We therefore
conclude, as did Holm and Hammarstrom
(1973), that red-cell lysis is a consequence
of close cell-surface contact and subse-
quent phagocytosis.
Aggregated IgG
Samples of heat-aggregated and mono-
meric human IgG, obtained by column
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FIG. 4. Inhibition of monocyte-mediated
lysis of red cells by serial dilutions of
aggregatecd human IgG. * *, aggre-
gated IgG; O O , monomeric IgG.
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6 observation suggests that binding tothe Fe
receptor of the effector cell is an integral
feature of the lysis of antibody-treated
erythrocytes.
Dose-response curves
Since serial dilutions of effector cells
were tested, the 51Cr-release data obtained
from this assay provide dose-response
curves when plotted against the number
of NSE+ cells added. The dose-response
curves are linear up to about 20% lysis,
and we therefore decided to employ this
initial part of the curve to derive a para-
meter for quantitative expression of
monocyte lytic capacity. Sample dose-
response curves from normal volunteers
and melanoma patients are shown in
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FIG. 5. Sample dose-response curves show-
ing derivation of parameter EL15 (i.e.
number of monocytes inducing 15% 51Cr
release). 0 -*, melanoma patient;
0 --- O, normal (lonor.
Fig. 5. The parameter derived from
such curves was the dose of NSE+ mono-
nuclear cells required to provide 15% 51Cr
release from the target cells (the lower
the cell dose needed, the more active the
monocytes). This parameter, referred to
as the EL15 (erythrocyte lysis 15%0) was
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FiTh. 6. Frequency distribution histograms
showing EL15 for all melanoma patients
and normal (ionors. Mean EL15 for normal
donors = 7-6 ± 3-4 x 105 monocytes/ml.
Mean EL15 for melanoma patients = 4-8 ±
3-2 x 105 monocytes/ml. Note that a
lower EL15 (lenotes increased monocyte
activity.
used since in that form the data appear to
be normally distributed and are therefore
suitable for parametric statistical evalua-
tion. Histograms were constructed for the
EL15 for all normal donors and melanoma
patients (Fig. 6).
Lytic activity ofpatients' monocytes
The data obtained from the normal
donors and patients are shown as the EL15
in the Table.
When the data from all the patients
were compared to the normal donors it is
clear that there is a significant difference
(P < 0 01 in the two-sample t test) with
the patients having the lower EL15.
However, using the same test for signifi-
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TABLE. MeanEL15forMelanomaPatients
and NVormal Controls
Normal cointrols
All melanoma patients
All high-risk patients
All mlisseminate(Ipatielnts
No.
27
36
21
1 5
Mean
EL15 X
10-5/ml
7-6 + 3-4
4-8 ± 3-2
4-6 3-5
5-1 2-9
cance, there is no detectable difference
between patients with minimal disease
and those with widespread dissemination
(P > 0t5).
Since the patients have a significantly
lower mean EL15 than the normal donors
(Fig. 6) we conclude that on average the
monocytes of our melanoma patients are
significantly more active in this lytic
assay than those of normal individuals.
Detailed stage and prognostic correlations
will need to be evaluated in larger patient
groups, since these studies were not
designed to look for detailed stage correla-
tions.
The data can be expressed in other ways
less amenable to statistical manipulation.
Over the linear part of the dose-response
curves, it is possible, knowing the number
of target cells in each well, the 51Cr
release and the number of NSE+ effector
cells, to calculate the number of erythro-
cytes killed by each monocyte. From the
sample curve in Fig. 5, it can be shown
that, in the normal donor illustrated, 038
erythrocytes were lysed by each monocyte,
whereas the patient gave a value of 1. 0
red cells/monocyte (i.e. at 15% release the
patient's monocytes showed -,3 x the
normal lytic activity).
Four of the patients were tested before
and after chemotherapy and there was no
evidence of any significant effect on mono-
cyte-mediated lysis. However, the chemo-
therapy was given in high doses at monthly
intervals, and the observations in these 4,
and indeed in all 19 treated patients, were
made 2 to 4 weeks after the last dose of
drug.
DISCUSSION
We have adapted the phenomenon of
monocyte-mediated lysis of antibody-
coated human red cells, described origin-
ally by Holm and Hammarstr6m (1973)
to develop a clinically applicable micro-
assay for the general investigation of
monocyte function. Since the events lead-
ing to the release of label from the red
cells are complex, and involve binding
to Fe receptors, phagocytosis and intra-
cellular lysis, the assay should be a
suitable one for detecting defects anywhere
in this series of events. Like Holm and
Hammarstrom (1973) we conclude that
the effector cell is mononuclear, adherent
and phagocytic, can be blocked by aggre-
gated IgG and its presence is always
associated with NSE+ cells. We therefore
believe this cell to be a monocyte. How-
ever, we also find that granulocytes can
lead to lysis of target cells, although they
are considerably less active on a cell-for-
cell basis than monocytes. By chlor-
acetate esterase (CAE) staining of the
cell suspensions it is possible to detect
granulocyte (even left-shifted) contamina-
tion and to discard those preparations
with an unacceptably high granulocyte
content. The use of serial dilutions of
effector cells allowed us to construct dose-
response curves showing the relationship
between red-cell lysis and the number of
NSE+ cells. From these curves, a simple
parameter was derived expressing the
lytic activity of the cell preparation as
the number of monocytes (NSE+ cells)
required to produce 15% lysis.
Since we had, somewhat naively, ex-
pected defective monocyte function in the
patients, we were surprised by our results,
which indicate that melanoma patients,
treated or untreated, show a significant
increase in monocyte-mediated lysis over
a group of normal healthy donors. There
was no clear-cut correlation with clinical
stage, but since these assays were not
set up to detect detailed differences in
disease burden, only a very powerful
effect would have been detected.
Rodent macrophages can be activated
by a variety of stimuli. This "activation"
can be characterized by many different
functional criteria, including enhanced
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phagocytosis and spreading, increased
bactericidal activity, cytostasis and cyto-
lysis of transformed cells, and an assort-
ment of biochemical changes, including
enhanced hexose monophosphate shunt
(HMPS) activity. King, Bain and Lobuglio
(1975) have claimed that the monocytes of
patients with either tuberculosis or cancer
show increased staphylocidal activity, and
suggest that this is a consequence of
monocyte activation, since HMPS activity
is also increased in some cancer patients
(King, Lobuglio and Sagone, 1977) as is
the expression of Fc receptors (Lobuglio,
1970; Rhodes, 1977).
Poplack et al. (1976) have also used the
lysis of antibody-coated human erythro-
cytes as an assay for monocyte function,
and have applied it to patients with
Wiskott-Aldrich syndrome. Despite
normal peripheral-blood monocyte counts
these patients showed a severe defect
in monocyte lytic activity. The peri-
pheral-blood monocyte counts in our
patients were also within the normal range,
and our data indicate an increase in
monocyte lytic activity in malignant
melanoma.
Currently available information suggests
that the monocytes of cancer patients
show depressed chemotaxis and depressed
maturation, but these defects are asso-
ciated with enhanced Fc receptor expres-
sion, increased staphylocidal activity,
increased hexose-monophosphate shunt
activity and, from our present work, an
increase in the capacity to lyse antibody-
coated erythrocytes. These features could
all be the consequence of monocyte
"activation". A cell whose metabolic and
enzymatic activities have been stimulated
may well lose the capacity to respond to
chemotactic stimuli and to mature. Such
an hypothesis may also explain the data of
Eccles and Alexander (1974) who showed
that in animals bearing tumours with a
high macrophage content there is a sub-
stantial defect in their capacity to mount a
monocyte/macrophage infiltrate at distant
sites of inflammation. Since, as they have
shown, this is not due to a quantitative
monocyte deficiency, an intrinsic qualita-
tive change in monocyte function may be
responsible. "Activation", possibly media-
ted by immune complexes, could well
account for these observations. However,
the nature of the stimulus responsible for
monocyte activation in our patients is as
yet unclear. Pike and Snyderman (1976)
have suggested that decreased macrophage
chemotaxis in tumour-bearing animals
may be mediated by a humoral factor. An
investigation of the role of serum compo-
nents in several assays of monocyte
function will be published separately.
These studies were supporte(l by a programme
grant from the Medical Research Council. G.A.C.
thanks the Cancer Research Campaign for financial
support.
REFERENCES
BOETCHER, D. A. & LEONARD, E. J. (1974) Abnormal
Monocyte Chemotactic Responses in Cancer
Patients. J. nato. Cancer Inst., 52, 1091.
BOYuM, A. (1968) Isolation of Mononuclear Cells
and Granulocytes from Human Blood. Scand. J.
Clin. Lob. Invest., 21, 77.
COHN, Z. A. (1970) Endocytosis and Intracellular
Digestion. In Mononuclear Phagocytes. Ed. R. Van
Furth. Oxford: Blackwell. p. 121.
CITRRIE, G. A. & HEDLEY, D. W. (1977) Monocytes
an(d Macrophages in Malignant Melanoma. I.
Peripheral Bloodl Macrophage Precursors. Br. J.
Cancer, 36, 1.
DIZoN, Q. & SOUTTHAM, C. M. (1963) Abnormal
Cellular Responses to Skin Abrasions in Cancer
Patients. Cancer, N.Y., 16, 1288.
ECCLES, S. A. & ALEXANDER, P. (1974) Sequestra-
tion of Macrophages in Growing Tumours and its
Effect on the Immunological Capacity ofthe Host.
Br. J. Cancer, 30, 42.
HAUSMAN, M. S., BROSMAN, S., SNYDERMAN, R.,
MICKEY, M. R. & FAHEY, J. (1975) Defective
Monocyte Function in Patients with Genitouri-
nary Carcinoma. J. natn. Cancer Inst., 55, 1047.
HOLM, G. & HAMMARSTR6M, S. (1973) Haemolytic
Activity of Human Blood Monocytes. Clin. exp.
Immun., 13, 29.
KING, G. W., BAIN, G. & LOBUCGLTO, A. F. (1975)
The Effect of Tuberculosis and Neoplasia on
Human Monocyte Staphylocidal Activity. Cell
Immunol., 16, 389.
KINC1, G. W., LOBUGLIO, A. F. & SAGONE, A. L.
(1977) Human Monocyte Glucose Metabolism in
Lymphoma. J. Lab. cldti. Med., 89, 316.
LOBUGLIO, A. F. (1970) Effect of Neoplasia on
Human Macrophage Membrane Activity. J. Lab.
clin. Med., 76, 888.
MCVIE, J. G., LOGAN, E. C. M. & KAY, A. B. (1977)
Monocyte Function in Cancer Patients. Eur. J.
Cancer, 13, 351.
PIKE, M. C. & SNYDERMAN, R. (1976) Depression
of Maciophage Function by a Factor Produced by
23344 R. E. NYHOLM AND G. A. CURRIE
Neoplasms: A Mechanism for Abrogation of
Immune Surveillance. J. Immun., 117, 1243.
POPLACK, D. G., BONNARD, G. B., HOLIMAN, B. J.
& BLAEsE, R. M. (1976) Monocyte-mediated
Antibody-dependent Cellular Cytotoxicity: A
Clinical Test of Monocyte Function. Blood, 48,
809.
REODES, J. (1977) Altered Expression of Human
Monocyte Fc Receptors in Malignant Disease.
Nature, Lond., 265, 253.
YAM, L. T., Li, C. Y. & CROSBY, W. H. (1971)
Cytochemical Identification of Monocytes and
Granulocytes. Am. J. Clin. Path., 55, 283.